Clinical trials: Antiretroviral Therapy, Highly Active
Hepatitis C, HIV Infections
Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV
The purpose of this study is to measure the effects of anti-HIV drugs on hepatitis C virus (HCV) viral load in people infected with both HCV and HIV.
- Trial name
- ART and HCV (NCT00545558)
- Testing
- Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of Cincinnati
HIV Infection, HAART-treated
Dolutegravir + Rilpivirine Switch Study (DORISS)
The primary objective of the study is to evaluate the capacity of Dolutegravir + Rilpivirine vs. continued triple combination HAART to maintain plasma HIV RNA ≤ 50 copies/ml throughout 24 weeks in patients with plasma HIV RNA ≤…
- Conditions
- HIV Infection, HAART-treated, Virologically Controlled
- Trial name
- DORISS (NCT02069834)
- Testing
- Arm 1 (intervention), Arm 2 (control)
- Where
- 25 sites in France
- Sponsor
- Nantes University Hospital
HIV Infections
A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients
The purpose of this study is to determine the safety of anti-HIV drugs combined with low-dose chemotherapy (consisting of cyclophosphamide [CTX]) in HIV-positive patients.
- Trial name
- NCT00000899
- Testing
- Nelfinavir mesylate, Lamivudine, Filgrastim
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection, Osteopenia
Effect of HIV Infection and Highly Active Antiretroviral Treatment (HAART) on Bone Homeostasis
Advances in HAART have been a huge success story in the management of HIV infection. However, serious metabolic complications including osteoporosis and bone fractures are increasingly been seen with HAART, and the responsible…
- Conditions
- HIV Infection, Osteopenia, Osteoporosis
- Trial name
- OPG-2 (NCT01020045)
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Emory University
HIV Infections, Hepatitis C
The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin
This study will evaluate how controlling HIV infection with HAART (highly active antiretroviral therapy) affects the response to hepatitis C treatment with peginterferon alpha-2b and ribavirin in HIV-infected patients with…
- Trial name
- NCT00031343
- Testing
- highly active antiretroviral therapy (HAART)
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328
The purpose of this study is to determine the effects of an HIV vaccine (Remune) on the immune system. This study involves patients who have received at least 60 weeks of anti-HIV therapy, either alone or in combination with…
- Trial name
- NCT00000943
- Testing
- Tetanus Toxoid Vaccine, Hepatitis A Vaccine (Inactivated), HIV-1 Immunogen
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART
To ascertain the effect of thalidomide on immune responses to vaccination with polyvalent pneumococcal polysaccharide vaccine and tetanus toxoid in HIV-infected patients; particularly, on markers of immune activation and…
- Trial name
- NCT00002392
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Rockefeller University
HIV, Community Health Workers
The Impact of Home Delivery of Antiretroviral Therapy on Virological Suppression
Home delivery of antiretroviral therapy (ART) by community health workers (CHWs) has the potential to reduce key barriers to ART care retention.
- Conditions
- HIV, Community Health Workers, Antiretroviral Therapy, Highly Active
- Trial name
- NCT02711293
- Testing
- ART home delivery, Enhanced nutrition counseling
- Where
- Tanzania
- Volunteers
- 2,172 people
- Sponsor
- Harvard School of Public Health (HSPH)
HIV Infections
HIV Expression in Patients With Low Viral Load on Highly Active Antiretroviral Therapy (HAART)
This study will investigate low-level viral loads in HIV-infected patients taking highly active antiretroviral therapy (HAART). Although HAART reduces viral levels and restores immune function to some degree, it does not cure HIV…
- Trial name
- NCT00043641
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
Strategic Timing of Antiretroviral Treatment
Objectives: To find out if the chance of developing a serious illness or of getting AIDS is less if patients start taking HIV medicines at a time when their cluster-of-differentiation-4 (CD4)+ cell count is still fairly high…
- Trial name
- START (NCT00867048)
- Testing
- All licensed antiretroviral medications
- Where
- 218 sites in United States, Argentina and 34 more
- Volunteers
- 4,688 people
- Sponsor
- University of Minnesota
HIV Infections
Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication
The purpose of this study is to see if the amount of stem cells (cells that can develop into many kinds of cells) in the blood before anti-HIV drugs are taken can predict if the immune system will become stronger after anti-HIV…
- Trial name
- NCT00006578
- Testing
- Ritonavir, Abacavir sulfate, Amprenavir
- Where
- 5 sites in United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Management of Highly Active Anti-retroviral Therapy-related Hyperlipidemia Among HIV-infected Patients in Taiwan
1. Written informed consent must be obtained before any study specific procedures are undertaken. 2. The process of the experiment (brief describe) The patients must come back for follow during 4 to 12 weeks after starting the…
- Trial name
- NCT01697540
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Acquired Immunodeficiency Syndrome
Longitudinal Study of HAART, Social Networks, & Adherence
Our study is a randomized controlled trial that aims to evaluate the effectiveness of modified directly observed therapy (mDOT) to (1) increase both short and long term adherence to HAART treatment, and (2) improve clinical…
- Trial name
- NCT00272220
- Testing
- modified directly observed therapy (mDOT)
- Where
- Mozambique
- Volunteers
- 350 people
- Sponsor
- University of Washington
HIV Infections
Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Infected Patients
HIV-1-infected patients who have been treated with anti-HIV drugs for a long time may have weakened immune responses to HIV. The DNA-based vaccine in this study is designed to boost the immune system's responses against many…
- Trial name
- NCT00052182
- Testing
- EP HIV-1090
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, HIV Infections
TB (Tuberculosis) Preventive Therapy for HIV Patients With Access to HAART (Highly Active Antiretroviral Therapy)
The purpose of this study is to determine if implementing a policy of widespread INH (Isoniazid) prophylaxis therapy in HIV-infected patients with access to antiretroviral therapy reduces the incidence of active TB disease in the…
- Trial name
- NCT00107887
- Testing
- INH preventive therapy, TST (tuberculin skin test)
- Where
- Brazil
- Volunteers
- 17,415 people
- Sponsor
- Johns Hopkins University
HIV Infections, Hepatitis B
Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV
This study will evaluate the drug telbivudine (LdT) for treatment of hepatitis B virus (HBV) in HIV infected patients. Patients will take telbivudine alone for 24 weeks, add anti-HIV drugs for 24 weeks, then stop taking…
- Trial name
- NCT00051090
- Testing
- Telbivudine, Lamivudine, Efavirenz
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children
The primary objective of this study is to assess the efficacy of switching to tenofovir disoproxil fumarate (TDF) compared to continuing stavudine or zidovudine in maintaining virologic suppression in HIV-1 infected children.
- Trial name
- NCT00528957
- Testing
- Tenofovir DF, Zidovudine, Stavudine
- Where
- 9 sites in United States, Panama and 1 more
- Volunteers
- 97 people
- Sponsor
- Gilead Sciences
HIV Infections
Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy
The purpose of this study is to assess the safety and efficacy of tenofovir disoproxil fumarate (tenofovir DF; TDF) plus a genotype-guided optimized background regimen (OBR) compared to placebo plus OBR in the treatment of human…
- Trial name
- NCT00352053
- Testing
- Tenofovir DF
- Where
- 18 sites in Brazil, Panama
- Volunteers
- 87 people
- Sponsor
- Gilead Sciences
HIV Infections
Observational Cohort of HIV Infected Adults and Children in the PHPT Network Hospitals in Thailand
Since 2004, the Thai Ministry of Public Health has massively scaled up antiretroviral treatment programs to provide therapy to more than 80,000 patients with partial support of the Global Fund to fight AIDS, Tuberculosis and…
- Trial name
- NCT00433030
- Where
- 38 sites in Thailand
- Volunteers
- 2,816 people
- Sponsor
- Institut de Recherche pour le Developpement
HIV Infections
An Enhanced Adherence Support Programme for Highly Active Antiretroviral Therapy (HAART)
In southern Africa, TB is the most common first AIDS-defining condition. Initiating Antiretroviral therapy (ART) in HIV positive TB patients will lead to the inclusion of the majority of HIV/AIDS patients currently fulfilling the…
- Trial name
- eASP (NCT00408642)
- Testing
- Enhanced adherence support, Standard adherence support
- Where
- South Africa
- Volunteers
- 297 people, healthy volunteers welcome
- Sponsor
- Centre for the AIDS Programme of Research in South Africa